Medical gear firms told to 'promptly' flag adverse cases

Indian medical device firms must now promptly report all adverse events, both serious and non-serious, to the government's Materiovigilance Programme. This directive aims to boost patient safety and address concerns over underreporting of issues linked to locally manufactured equipment. Timely reporting is crucial for identifying risks and implementing necessary safety measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2hCVEeT
via IFTTT

Read More

US tariff cut to 18% to boost India’s medical device exports

India's medical device exports to the US will surge following a tariff cut. This move makes Indian products more competitive against China. Lower import duties will also benefit India's healthcare system by reducing costs for high-value equipment. Industry leaders hail the deal as transformative, unlocking significant market potential and fostering investment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TvIA4rh
via IFTTT

Read More

Budget relief on the label: Govt proposes to drop duty on rare disease drugs

The Indian budget proposes exempting seven rare disease drugs from import duties. This move aims to lower costs for expensive life-saving medicines. Patient groups welcome the relief for out-of-pocket expenses. However, some believe duty cuts alone will not make these drugs affordable for most Indians. The proposal also includes duty waivers on anti-cancer drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g10ExeW
via IFTTT

Read More

Lupin rolls out generic oncology drug in US market

Drug firm Lupin has launched a generic cancer treatment medication in the US. The company introduced Dasatinib Tablets in various strengths. This product is bioequivalent to Sprycel Tablets. It is indicated for adults with Philadelphia chromosome-positive chronic myeloid leukemia. The US market for Dasatinib Tablets had significant sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WhdD0eY
via IFTTT

Read More

Budget 2026 gives biologics & biosimilars a major policy boost

India is set to become a global biopharmaceutical manufacturing hub. Finance Minister Nirmala Sitharaman announced a dedicated ₹10,000 crore program over five years. This initiative focuses on biosimilars and biologics, crucial for treating non-communicable diseases. The move aims to boost manufacturing, regulation, and clinical trials, positioning India for future global competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5kjGqs
via IFTTT

Read More

Union Budget 2026: Govt to overhaul drug regulator CDSCO, announces Rs 10,000 crore ‘Biopharma Shakti’ push

India Budget 2026: India's drug regulatory authority, CDSCO, will be strengthened to meet global standards and speed up approvals. A new initiative, Biopharma Shakti, with a Rs 10,000 crore outlay over five years, will boost domestic production of biologics and biosimilars. This strategy includes establishing 1,000 accredited clinical trial sites and upgrading NIPERs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Sfmg2YO
via IFTTT

Read More

Budget 2026: Sitharaman launches 'Biopharma Shakti' with a Rs 10,000-crore bet to heal India, power manufacturing

Union Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceutical manufacturing. Finance Minister Nirmala Sitharaman revealed plans to inject Rs 10,000 crore into this sector over the next five years. This initiative will significantly enhance domestic production of biologics and biosimilars.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVWtc6x
via IFTTT

Read More